A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)


Some of the key differences between Lanreotide and Octreotide long-acting are:

1.  Octreotide long-acting needs constituting prior to administration – Lanreotide comes prefilled. 

2. Octreotide long-acting is administered intra-muscular, Lanreotide is deep subcutaneous. 

3.  I probably should add Octreotide LAR cannot be self-injected but Lanreotide can.  I suspect this type of delivery system may open up that possibility for Octreotide LAR. 

So, this clinical trial caught my eye.  A version of octreotide long-acting which is prefilled and given subcutaneously.  Plus, the manufacturers say it has a much higher bioavailability than the standard product Sandostatin LAR (bioavailability is the proportion of a drug or other substance which enters the circulation when introduced into the body and so is able to have an active effect).

CAM2029 might therefore be considered a generic of Sandostatin LAR but better both in the delivery system and bioavailability. 

What is CAM2029?

CAM2029 is developed for the treatment of acromegaly and neuroendocrine tumors. The product candidate offers important potential advantages over currently marketed products, including easy administration, significantly increased bioavailability, and potential for enhanced treatment efficacy in patients for whom current treatments provide suboptimal treatment effects.

CAM2029 is a ready-to-use, long-acting subcutaneous injection depot based on the active substance octreotide formulated with Camurus’ proprietary FluidCrystal® injection depot technology. It is provided as a prefilled syringe, thus not requiring any reconstitution or conditioning prior to administration. Due to the superior ease of handling and administration, CAM2029 can be conveniently administered by the patients themselves.

CAM2029 – Key target attributes
• Subcutaneous long-acting octreotide
• Fast onset and one month duration of therapeutic plasma-levels
• Provided ready-for-use in prefilled syringes for easy self-administration
• Compatible with autoinjectors
• High bioavailability – 500% higher than Sandostatin® LAR®, with potential for better treatment effects in some patients

CAM2029 – Key publications
1. Octreotide SC depot in patients with acromegaly and functioning neuroendocrine tumors: a phase 2, multicenter study
Pavel M, Borson‑Chazot F, Cailleux A, Hörsch D, Lahner H, Pivonello R, Tauchmanova L, Darstein C, Olsson H, Tiberg F, Ferone D., Cancer Chemotherapy and Pharmacology (2019) 83:375–385

2. Camurus announces dosing initiated in Phase 3 study of CAM2029 in patients with Neuroendocrine Tumors. 

The Sorento Clinical Trial

Purpose: The purpose of this study is to compare the effectiveness and safety of CAM2029 to both Octreotide LAR (Sandostatin LAR) or Lanreotide Autogel in patients with advanced, well-differentiated GEP-NET. Patients who experience progressive disease in the randomized part of the study may proceed to an open-label extension part with intensified treatment with CAM2029.

Who can take part?  Make sure you read all of the inclusion and exclusion details in the clinical trial.  I picked out a key one for each.  Included – Histologically confirmed, advanced (unresectable and/or metastatic), and well-differentiated NET of GEP or presumed GEP origin. Excluded – Previously received radioligand therapy (PRRT) at any time.

Where are the trials taking place? United States (Texas), Italy, Spain (4 hospitals). The principal investigator is well-known Canadian NET specialist Simron Singh MD.  They are looking for 300 participants across all sites. Recruiting now according to the clinical trials document. 

The full clinical trial document can be found here

Great video of FluidCrystal® injection depot from the manufacturer but it’s not clear whether any authorised drug delivery system would look like this, it could be a prototype and/or just for clinical trial use. 

General Clinical Trials Disclaimer

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided in the clinical trials document. It’s very important to check the trial inclusion and exclusion criteria before making any contact.  If you need questions, the articles here is very useful Questions to Ask About Clinical Trials | Cancer.Net

The inclusion of any trial within this blog should not be taken as a recommendation by Ronny Allan. 


Subscribe to my newsletter

Thanks for reading.


I’m also active on Facebook. Like my page for even more news. Help me build up my new site here – click here and ‘Like’

Sign up for my newsletters – Click Here


My Diagnosis and Treatment History

Follow me on twitter

Check out my online presentations

Check out my WEGO Health Awards

Like my new awareness page – click here or on the photo.  (Like rather than follow please!)

Check out my Glossary of Terms – click here

patients included

Please Share this post for Neuroendocrine Cancer awareness and to help another patient


RonnyAllan.NET – Summary of January 2023 – Ronny Allan – Living with Neuroendocrine Cancer

Summary Great start to 2023 and I thank those who continue to support my social media and this blog.  I’m keen to hear any suggestions

Read More »

Phase I study of procaspase-activating compound-1 (PAC-1) in the treatment of advanced malignancies (incl NET)

Trial Summary This interesting trial is a multi-cancer effort including NET.  The phase I clinical trial of Procaspase Activating Compound-1 (PAC-1), a drug that spurs

Read More »

Dustin Diamond

I’m behind the curve on this one after being ahead on celebrities such as Steve Jobs, Aretha Franklin, Wilko Johnson and Olivia Williams.  But in

Read More »

Neuroendocrine tumors are uncommon but definitely not rare

USA finally commits  UK and Australian figures recently confirmed that Neuroendocrine Cancer is the 10th and 7th most common cancer type.  It was great to

Read More »

Cancer Ablation

What is Cancer Ablation? This is a minimally invasive surgical method to treat solid cancers. Special probes are used to “burn” or “freeze” cancers. Computed

Read More »

Lactose intolerance – the NET Effect

Background   When I cast my mind back to my very first surgery, I remember asking my Oncologist what I could do to put on weight. 

Read More »

EUS Guided Ablation for small pancreatic NETs (Less than 2cm)

To burn or not to burn? I once wrote a post about Pancreatic NET “to cut or not to cut”.  You can read that here. 

Read More »

RonnyAllan.NET – a review of 2022

Review In 2022, my pet project (my blog) hit 2 million views in early November – that was a major boost.  It takes 3-4 years to get

Read More »

RonnyAllan.NET – Summary of December 2022

Summary December is always the quietest month of the year, no surprise why!  However, the top 10 below is somewhat surprising, I guess some posts

Read More »

6 thoughts on “A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot (CAM2029) in Patients With GEP-NET (SORENTO)

I love comments - feel free!

%d bloggers like this: